BioMimetic Therapeutics Receives First Orthopedic Marketing Approval for Augment™ Bone Graft

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft... [read full story]                    

powered by
Add Comment
There are also 10 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies